Genmab A (GMAB) Change in Receivables (2023 - 2026)

Genmab A (GMAB) has reported Change in Receivables for 4 consecutive years, with -$259.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Receivables fell 236.36% year-over-year to -$259.0 million; the trailing twelve-month figure through Jun 2026 stood at -$302.0 million (up 19.68% YoY), and the FY2025 full-year result was -$166.0 million, up 27.83% from the prior year.
• Change in Receivables declined to -$259.0 million in Q2 2026 per GMAB's latest filing, from $158.0 million in the prior quarter.
• Across five years, Change in Receivables topped out at $158.0 million in Q1 2026 and bottomed at -$614.0 million in Q4 2023.
• Historically, Change in Receivables has averaged -$132.7 million across 4 years, with a median of -$137.5 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Change in Receivables surged 217.95% in 2025, then sank 236.36% in 2026.
• Over 4 years, Change in Receivables stood at -$614.0 million in 2023, then soared by 62.54% to -$230.0 million in 2024, then jumped by 46.09% to -$124.0 million in 2025, then sank by 108.87% to -$259.0 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered -$259.0 million, $158.0 million, and -$124.0 million for Q2 2026, Q1 2026, and Q3 2025 respectively.